

# Spiro

Spiro has delivered well during its pilot and is now experimenting with technical assistance to state health departments, which would turbocharge its scale. They have already received a GiveWell grant and the Global Fund is an obvious payer-at-scale. A strong bet.

**Overall Rating** ★★★★★

**Cost Effectiveness Rating** ★★★★★

**Cost Effectiveness Rationale** 14x  
GiveWell Benchmark


**Our Recommendation** [Buy](#) ✓

## Key Information


### OVERVIEW

Spiro conducts household screening and treatment for tuberculosis in Pakistan, offering on-the-spot treatment for children under 5 in a single visit.

REGISTRATION	TURNOVER (USD)	STAGE	COUNTRIES ACTIVE
US	\$597k	Early mid-stage	Pakistan



## The UP Index™ 3.4 / 5



### Impact Metrics

Death prevented (per \$1M at scale)	255
Confidence	Medium
<b>COST PER DALY AVERTED</b>	<b>TOTAL ANNUAL REACH</b>
\$46	9,800 cases treated

### International Evidence

**Intervention Evidence Quality** Medium  
Rationale: Single RCT

Quasi-Experimental	✓
Single RCT	✓
Multiple RCTs	✗
Meta-Analysis	✗

### Pathways to Scale

<b>PAYER-AT-SCALE INTEREST</b>	<b>GOVERNMENT ADOPTION</b>
★★★★★	★★★★★
<b>FRANCHISE/REPLICATION (BY OTHER NGOS)</b>	<b>COMMERCIAL REVENUE</b>
★★★★★	★★★★★

### Implementation Evidence

**Organisation / Programme Evidence Quality** Medium  
Rationale: Successful pilot

Pilot Study	✓
Quasi-Experimental	✗
Single RCT	✗
Multiple RCTs	✗